Bioimpact Capital LLC

-

Assets, Funds, Holdings

Home | Sign Up | Log In
New Features
Latest Fund Raises
Related People
Fund Service Providers
Startup & Company Raises
List of Funds
Boston Firms
Boston Hedge Funds
Cornell Alumni Firms
CalPERS Portfolio
NYSCRF Portfolio
User Guide
Regulatory AUM vs AUM
LP Portfolios
Related Firms
Build a Portfolio
Comprehensive Search
Keyboard
Bioimpact Capital LLC
CRD #309865
SEC #801-119133
CIK #0001796461, 0001687078, 0000168707
AUM
Employees 50 (62% Investors, 0% Brokers)
Fees
Minimum
Phone617-425-9200
Address399 Boylston Street
Boston, MA 02116
Source [IAPD] [EDGAR] [Website] [Twitter] [LinkedIn]
Total AUM ($B)
3.02.41.81.20.60.02009201420192025
Fees and Compensation — Form ADV Part 2A (11/17/2022) [Brochure]
Item 5.    Fees and Compensation

The Adviser, or its affiliates, generally receive Advisory Fees and either Performance Allocations
or Carried Interest (each as defined below) or similar performance-based remuneration from a
Fund. A Fund, and/or its portfolio companies may also make other payments to the Adviser or its
affiliates for services provided to the portfolio companies which, in certain circumstances, may
reduce the Advisory Fees payable to the Adviser. Additionally, consistent with the Organizational
Documents of a Fund, the Fund typically bears certain out-of-pocket expenses incurred by the
Adviser in connection with the services provided to the Fund and/or the portfolio companies.
Further details about certain common fees and expenses are set forth below.

Advisory Fees

As compensation for investment supervisory services rendered to the Funds, the Adviser receives
from each such Fund an advisory fee (each, an “Advisory Fee”) typically calculated based on
committed capital or net asset value, with respect to such Fund. Advisory Fees may be reduced
during the life of a Fund. The precise amount of, and the manner and calculation of, the Advisory
Fees for each Fund are established by the Adviser and are set forth in such Fund’s Organizational
Documents. The Advisory Fees and other fees and distributions described herein are generally
subject to modification, waiver, or reduction by the Adviser in its sole discretion, both voluntarily
and on a negotiated basis with selected investors via side letter and other arrangements, which may
not be disclosed to other investors in the same Fund. The fee structures described herein may be
modified from time to time. Fees may differ from one Fund to another, as well as among investors
in the same Fund.

The Advisory Fees paid by certain Funds will generally be reduced by (1) the amount of fees paid
by such Fund to persons acting as a placement agent in connection with the offer and sale of
interests in such Fund to certain potential investors, (2) the fees incurred by the Adviser in
connection with the organization of such Fund that exceed a limit specified in such Fund’s
Organizational Documents, and/or (3) certain other fees (see Other Fees and Expense
Reimbursement below) received by the Adviser or its affiliates. The amount and manner of such
reduction, if any, is set forth in the Organizational Documents of the applicable Fund.

Advisory Fees vary Fund by Fund and are either payable quarterly or monthly in advance. There
are also legacy Advisory Fee and performance fee structures that are generally no longer available
to new investors.

Certain investors in the Funds that are employees, business associates, and other “friends and
family” of the Adviser, its affiliates or their personnel, including any related entity established by
any of the foregoing, such as trusts, charitable programs, endowments or related programs, family
investment vehicles and other estate planning vehicles (collectively, “Adviser Investors”) will
not typically pay Advisory Fees in connection with their investment in a Fund. Furthermore,
Adviser Investors do not generally bear any expenses incurred in making an investment and, as a
result, such expenses are generally borne by the Funds. Adviser Investors will only bear those
expenses specifically allocated solely to an Adviser Investor vehicle (for instance, formation
expenses, administrative fees, tax preparation fees, state filing fees and similar fees). The Adviser
may from time to time in the future establish certain investment vehicles through which certain

Adviser Investors, other “friends of the firm,” or other persons may invest alongside one or more
Funds in one or more investment opportunities. Such co-investment vehicles generally will not
pay Advisory Fees or Carried Interest.

The Adviser or an affiliated General Partner deducts Advisory Fees and Performance
Allocations/Carried Interest directly from Fund assets and does not bill investors in the Funds.

Upon termination, prepaid Advisory Fees are processed in accordance with the terms of the
applicable Advisory Agreement.

Performance Allocations

The affiliated General Partner of certain Funds receives performance-based compensation
generally equal to 20% of the excess net profit over net losses for each year for each investor,
subject to a high watermark (the “Performance Allocation”). The Performance Allocation is
generally made to the respective General Partner at the end of each year or sooner upon
withdrawals by investors. Please see Item 6 below regarding Performance Allocation.

Carried Interest Payments

With respect to certain Funds, a portion of the profits of each such Fund is distributed to its General
Partner, if any, as “carried interest” (the “Carried Interest”), generally equal to 20%. Please see
Item 6 below regarding Carried Interest.

Other Fees and Expense Reimbursement

Other Fees

In addition to the Advisory Fees, Performance Allocation, and Carried Interest, the Adviser and
its affiliates receive a variety of other cash, equity, and other non-cash fees relating to the
investment activities of certain Funds, their portfolio companies, and prospective portfolio
companies, including operational fees, and/or other similar fees received from portfolio companies
and/or prospective portfolio companies (collectively with the other fees described in this section,
“Other Fees”). The amount and timing of such fees received by the Adviser or its affiliates are
generally specified in the agreement or other documentation governing the applicable transaction.

In addition, the Adviser’s personnel, from time to time, receive stock of a portfolio company due
to the service of such personnel on the board of such portfolio company or as compensation for
other services provided to such portfolio company. In such event, the recipient will generally act
...
Account Minimums and Types of Clients — Form ADV Part 2A (11/17/2022) [Brochure]
Item 7.    Types of Clients

The Adviser currently provides investment supervisory services to the Funds. Investment advice
is provided directly to the Funds (subject to the direction and control of the General Partner or
board of directors of each such Fund, as applicable) and not individually to investors in such Fund.

Interests in the Funds are offered pursuant to applicable exemptions from registration under the
Securities Act and the 1940 Act. Investors in the Funds are generally “qualified purchasers” as
defined in the 1940 Act, and may include, among others, public pension plans, corporate pension
plans, endowments, private pension plans, foundations, insurance companies, fund-of-funds,
family offices, Operations Support Providers, other institutional investors, and high-net worth
individuals.

The Adviser does not have a minimum size for a Fund, but minimum investment commitments
may be established for investors in the Funds. The General Partner or board of directors of each
Fund may, in its sole discretion, permit investments below the minimum amounts set forth in the
Organizational Documents of such Fund.
CIK Period
0001796461 0001687078 0000168707
Sector Form 13F Holdings Value ($M)
DBV Technologies Sa 108.9
Cullinan Oncology Inc 108.7
Liquidia Corp 53.0
Alumis Inc 52.6
Edgewise Therapeutics Inc 52.3
Revolution Medicines Inc 49.3
Agios Pharmaceuticals Inc 44.2
Corcept Therapeutics Inc 39.7
Trevi Therapeutics Inc 39.4
Magenta Therapeutics Inc 35.6
Xenon Pharmaceuticals Inc 34.2
Helix Acquisition Corp 33.8
Desert Gateway Inc 33.7
Evommune Inc 33.5
Cytokinetics Inc 33.0
Syndax Pharmaceuticals Inc 31.3
Context Therapeutics Inc 28.0
Tocagen Inc 25.9
Marika Inc 25.7
Dyne Therapeutics Inc 25.5
Stoke Therapeutics Inc 25.0
Corvus Pharmaceuticals Inc 24.5
Relay Therapeutics Inc 23.5
Tarsus Pharmaceuticals Inc 23.1
Oric Pharmaceuticals Inc 22.9
Uniqure NV 22.4
Monte Rosa Therapeutics Inc 19.4
Natera Inc 18.6
Eliem Therapeutics Inc 17.8
 
 
Prev | Page 1 | Next
AUM Breakdown Accounts AUM ($B)
By Client Type
(a) Individuals (other than high net worth individuals) 0 0.0
(b) Individuals (high net worth individuals) 0 0.0
(c) Banking or thrift institutions 0 0.0
(d) Investment companies 0 0.0
(e) Business development companies 0 0.0
(f) Pooled investment vehicles 9 2.0
(g) Pension and profit sharing plans 0 0.0
(h) Charitable organizations 0 0.0
(i) State or municipal government entities 0 0.0
(j) Other investment advisers 0 0.0
(k) Insurance companies 0 0.0
(l) Sovereign wealth funds and foreign official institutions 0 0.0
(m) Corporations or other businesses not listed above 0 0.0
(n) Other 0 0.0
Total 9 2.0
By Discretionary
Discretionary 9 2.0
Non-Discretionary 0 0.0
Total 9 2.0
By Non-United States Persons
Non-United States Persons 1.9
United States Persons 0.1
Total 9 2.0
EDGAR Form CIK 2011 - 2026
13F-HR [0001687078]
3 [0001687078]
4 [0001687078]
SC 13D [0001687078]
SC 13G [0001687078]
13F-HR [0001796461]
SC 13G [0001796461]
Form 13D/13G Filer Form 13D/13G Subject Filed
MPM Bioimpact LLC Forte Biosciences Inc [2026-05-15]
MPM Bioimpact LLC DBV Technologies Sa [2026-02-17]
MPM Bioimpact LLC Climb Bio Inc [2026-02-17]
MPM Bioimpact LLC Compass Therapeutics Inc [2025-02-14]
MPM Bioimpact LLC Context Therapeutics Inc [2025-01-08]
Bioimpact Capital LLC Reunion Neuroscience Inc [2023-06-12]
Burrage Capital Management LLC Protalix Biotherapeutics Inc [2021-02-12]
Burrage Capital Management LLC Iveric Bio Inc [2019-12-12]
Firm Profile (Form ADV)
ServesInstitutional
Fund TypesHedge Fund
Form 3/4/5 Subject 2011 - 2026
Oncology Impact Fund Cayman Management LP
MPM Oncology Innovations Fund LP
Werewolf Therapeutics Inc
MPM BioImpact LLC
Gadicke Ansbert
UBS Oncology Impact Fund LP
MPM Asset Management LLC
MPM Oncology Innovations Fund GP LLC
iTeos Therapeutics Inc
TCR2 Therapeutics Inc
View All
Insider Transaction (Form 3/4/5) Date Action Shares Price Value ($)
Werewolf Therapeutics Inc HOWL
Common Stock
2025-12-04 Sell 83,230 $0.97 80,733
Werewolf Therapeutics Inc HOWL
Common Stock
2025-12-03 Sell 57,225 $0.87 49,786
Werewolf Therapeutics Inc HOWL
Common Stock
2025-12-02 Sell 59,277 $0.89 52,757
Werewolf Therapeutics Inc HOWL
Common Stock
2025-12-01 Sell 60,917 $0.94 57,262
Werewolf Therapeutics Inc HOWL
Common Stock
2025-11-28 Sell 20,277 $0.99 20,074
Werewolf Therapeutics Inc HOWL
Common Stock
2025-11-26 Sell 60,733 $0.98 59,518
Werewolf Therapeutics Inc HOWL
Common Stock
2025-11-25 Sell 42,533 $0.92 39,130
Werewolf Therapeutics Inc HOWL
Common Stock
2025-11-24 Sell 88,802 $0.98 87,026
Werewolf Therapeutics Inc HOWL
Common Stock
2025-11-21 Sell 64,331 $0.83 53,395
Werewolf Therapeutics Inc HOWL
Common Stock
2025-11-20 Sell 41,152 $0.89 36,625
Werewolf Therapeutics Inc HOWL
Common Stock
2025-11-19 Sell 66,324 $0.94 62,345
Werewolf Therapeutics Inc HOWL
Common Stock
2025-11-18 Sell 52,627 $0.93 48,943
Werewolf Therapeutics Inc HOWL
Common Stock
2025-11-17 Sell 57,061 $0.95 54,208
Werewolf Therapeutics Inc HOWL
Common Stock
2025-11-14 Sell 61,640 $0.93 57,325
Werewolf Therapeutics Inc HOWL
Common Stock
2025-11-13 Sell 90,951 $0.98 89,132
Werewolf Therapeutics Inc HOWL
Common Stock
2025-11-12 Sell 40,669 $1.09 44,329
Werewolf Therapeutics Inc HOWL
Common Stock
2025-11-11 Sell 55,810 $1.14 63,623
Werewolf Therapeutics Inc HOWL
Common Stock
2025-11-10 Sell 48,570 $1.18 57,313
Werewolf Therapeutics Inc HOWL
Common Stock
2025-11-07 Sell 68,480 $1.11 76,013
Werewolf Therapeutics Inc HOWL
Common Stock
2025-11-06 Sell 54,452 $1.21 65,887
showing 20 of 200 most recent transactions
Terms | Privacy | Providers | Companies | Guide
tony@aum13f.com